JP2016532703A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016532703A5 JP2016532703A5 JP2016536405A JP2016536405A JP2016532703A5 JP 2016532703 A5 JP2016532703 A5 JP 2016532703A5 JP 2016536405 A JP2016536405 A JP 2016536405A JP 2016536405 A JP2016536405 A JP 2016536405A JP 2016532703 A5 JP2016532703 A5 JP 2016532703A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- antigen
- binding fragment
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 claims description 82
- 102000036639 antigens Human genes 0.000 claims description 82
- 108091007433 antigens Proteins 0.000 claims description 82
- 239000012634 fragment Substances 0.000 claims description 82
- 239000000611 antibody drug conjugate Substances 0.000 claims description 39
- 229940049595 antibody-drug conjugate Drugs 0.000 claims description 39
- 108010002519 Prolactin Receptors Proteins 0.000 claims description 32
- 102100029000 Prolactin receptor Human genes 0.000 claims description 32
- 210000004027 cell Anatomy 0.000 claims description 30
- 239000008194 pharmaceutical composition Substances 0.000 claims description 16
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 11
- 229940127089 cytotoxic agent Drugs 0.000 claims description 11
- 239000002254 cytotoxic agent Substances 0.000 claims description 10
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 10
- 101100409237 Homo sapiens PRLR gene Proteins 0.000 claims description 9
- 108010057464 Prolactin Proteins 0.000 claims description 9
- 102000003946 Prolactin Human genes 0.000 claims description 9
- 230000001404 mediated effect Effects 0.000 claims description 9
- 229940097325 prolactin Drugs 0.000 claims description 9
- 210000004881 tumor cell Anatomy 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 7
- 230000011664 signaling Effects 0.000 claims description 7
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- 208000026310 Breast neoplasm Diseases 0.000 claims description 5
- 230000002401 inhibitory effect Effects 0.000 claims description 5
- 230000004614 tumor growth Effects 0.000 claims description 5
- 206010061968 Gastric neoplasm Diseases 0.000 claims description 2
- 101001123448 Homo sapiens Prolactin receptor Proteins 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 206010029098 Neoplasm skin Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- 208000037841 lung tumor Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000023958 prostate neoplasm Diseases 0.000 claims description 2
- 230000019491 signal transduction Effects 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims 4
- JJAHTWIKCUJRDK-UHFFFAOYSA-N succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate Chemical compound C1CC(CN2C(C=CC2=O)=O)CCC1C(=O)ON1C(=O)CCC1=O JJAHTWIKCUJRDK-UHFFFAOYSA-N 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 230000000903 blocking effect Effects 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 238000000034 method Methods 0.000 description 23
- 125000003275 alpha amino acid group Chemical group 0.000 description 8
- 229940124597 therapeutic agent Drugs 0.000 description 6
- 108010057085 cytokine receptors Proteins 0.000 description 4
- 102000003675 cytokine receptors Human genes 0.000 description 4
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 4
- 108010044540 auristatin Proteins 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 102100034608 Angiopoietin-2 Human genes 0.000 description 1
- 102000016989 Ciliary Neurotrophic Factor Receptor Human genes 0.000 description 1
- 108010000063 Ciliary Neurotrophic Factor Receptor Proteins 0.000 description 1
- 102100028471 Eosinophil peroxidase Human genes 0.000 description 1
- 108010054017 Granulocyte Colony-Stimulating Factor Receptors Proteins 0.000 description 1
- 102100039622 Granulocyte colony-stimulating factor receptor Human genes 0.000 description 1
- 101000924533 Homo sapiens Angiopoietin-2 Proteins 0.000 description 1
- 101001034652 Homo sapiens Insulin-like growth factor 1 receptor Proteins 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 description 1
- 102100020793 Interleukin-13 receptor subunit alpha-2 Human genes 0.000 description 1
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 description 1
- 102100026244 Interleukin-9 receptor Human genes 0.000 description 1
- 102100031775 Leptin receptor Human genes 0.000 description 1
- 102100021747 Leukemia inhibitory factor receptor Human genes 0.000 description 1
- 101710142062 Leukemia inhibitory factor receptor Proteins 0.000 description 1
- 108090000630 Oncostatin M Proteins 0.000 description 1
- 102100031942 Oncostatin-M Human genes 0.000 description 1
- 108010051742 Platelet-Derived Growth Factor beta Receptor Proteins 0.000 description 1
- 102100030485 Platelet-derived growth factor receptor alpha Human genes 0.000 description 1
- 101710148465 Platelet-derived growth factor receptor alpha Proteins 0.000 description 1
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 108040006873 interleukin-11 receptor activity proteins Proteins 0.000 description 1
- 108040003610 interleukin-12 receptor activity proteins Proteins 0.000 description 1
- 108040003607 interleukin-13 receptor activity proteins Proteins 0.000 description 1
- 108040002039 interleukin-15 receptor activity proteins Proteins 0.000 description 1
- 102000008616 interleukin-15 receptor activity proteins Human genes 0.000 description 1
- 108040006849 interleukin-2 receptor activity proteins Proteins 0.000 description 1
- 108040006856 interleukin-3 receptor activity proteins Proteins 0.000 description 1
- 108040006852 interleukin-4 receptor activity proteins Proteins 0.000 description 1
- 108040006859 interleukin-5 receptor activity proteins Proteins 0.000 description 1
- 108040006858 interleukin-6 receptor activity proteins Proteins 0.000 description 1
- 108040006861 interleukin-7 receptor activity proteins Proteins 0.000 description 1
- 108040006862 interleukin-9 receptor activity proteins Proteins 0.000 description 1
- 108010019813 leptin receptors Proteins 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361868185P | 2013-08-21 | 2013-08-21 | |
| US61/868,185 | 2013-08-21 | ||
| US201462012440P | 2014-06-16 | 2014-06-16 | |
| US62/012,440 | 2014-06-16 | ||
| US201462026088P | 2014-07-18 | 2014-07-18 | |
| US62/026,088 | 2014-07-18 | ||
| PCT/US2014/051831 WO2015026907A1 (en) | 2013-08-21 | 2014-08-20 | Anti-prlr antibodies and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019175762A Division JP2020023511A (ja) | 2013-08-21 | 2019-09-26 | 抗ｐｒｌｒ抗体及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016532703A JP2016532703A (ja) | 2016-10-20 |
| JP2016532703A5 true JP2016532703A5 (enExample) | 2017-10-05 |
| JP6621412B2 JP6621412B2 (ja) | 2019-12-18 |
Family
ID=51494506
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016536405A Active JP6621412B2 (ja) | 2013-08-21 | 2014-08-20 | 抗ｐｒｌｒ抗体及びその使用 |
| JP2019175762A Pending JP2020023511A (ja) | 2013-08-21 | 2019-09-26 | 抗ｐｒｌｒ抗体及びその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019175762A Pending JP2020023511A (ja) | 2013-08-21 | 2019-09-26 | 抗ｐｒｌｒ抗体及びその使用 |
Country Status (18)
| Country | Link |
|---|---|
| US (4) | US9302015B2 (enExample) |
| EP (1) | EP3036257B1 (enExample) |
| JP (2) | JP6621412B2 (enExample) |
| KR (1) | KR102343315B1 (enExample) |
| CN (1) | CN105793286B (enExample) |
| AU (1) | AU2014308920B2 (enExample) |
| CA (1) | CA2920369C (enExample) |
| CL (1) | CL2016000376A1 (enExample) |
| EA (1) | EA201600190A1 (enExample) |
| IL (1) | IL243974B (enExample) |
| MX (1) | MX370787B (enExample) |
| MY (1) | MY179851A (enExample) |
| NZ (1) | NZ716612A (enExample) |
| PH (1) | PH12016500349B1 (enExample) |
| SG (1) | SG11201601211TA (enExample) |
| TW (1) | TWI641620B (enExample) |
| UY (1) | UY35712A (enExample) |
| WO (1) | WO2015026907A1 (enExample) |
Families Citing this family (94)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3018144A1 (en) * | 2006-08-18 | 2016-05-11 | XOMA Technology Ltd. | Prlr-specific antibody and uses thereof |
| NZ631565A (en) | 2012-03-14 | 2016-07-29 | Regeneron Pharma | Multispecific antigen-binding molecules and uses thereof |
| EP2935331B1 (en) | 2012-12-24 | 2018-02-28 | AbbVie Inc. | Prolactin receptor binding proteins and uses thereof |
| AR095196A1 (es) | 2013-03-15 | 2015-09-30 | Regeneron Pharma | Medio de cultivo celular libre de suero |
| TWI641620B (zh) | 2013-08-21 | 2018-11-21 | 再生元醫藥公司 | 抗－ｐｒｌｒ抗體及其用途 |
| WO2015187596A2 (en) | 2014-06-02 | 2015-12-10 | Regeneron Pharmaceuticals, Inc. | Biologically active molecule conjugates, reagents and methods of manufacture, and therapeutic uses |
| KR20240142591A (ko) | 2015-03-27 | 2024-09-30 | 리제너론 파아마슈티컬스, 인크. | 메이탄시노이드 유도체, 이의 컨주게이트, 및 사용 방법 |
| MY189159A (en) | 2015-07-06 | 2022-01-29 | Regeneron Pharma | Multispecific antigen-binding molecules and uses thereof |
| TWI870789B (zh) | 2015-08-04 | 2025-01-21 | 美商再生元醫藥公司 | 補充牛磺酸之細胞培養基及用法 |
| KR20250133801A (ko) | 2015-12-08 | 2025-09-08 | 리제너론 파마슈티칼스 인코포레이티드 | 효소 내재화 조성물 및 방법 |
| CN105785607A (zh) * | 2016-03-31 | 2016-07-20 | 京东方科技集团股份有限公司 | 显示基板、点灯设备及点灯测试探针对位检测方法 |
| WO2017190079A1 (en) | 2016-04-28 | 2017-11-02 | Regeneron Pharmaceuticals, Inc. | Methods of making multispecific antigen-binding molecules |
| JP2019524687A (ja) | 2016-07-01 | 2019-09-05 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | 抗体薬物複合体およびこれを用いた治療方法 |
| EP3504328A1 (en) | 2016-08-24 | 2019-07-03 | Regeneron Pharmaceuticals, Inc. | Host cell protein modification |
| KR20250114431A (ko) | 2016-11-08 | 2025-07-29 | 리제너론 파마슈티칼스 인코포레이티드 | 스테로이드 및 이의 단백질-접합체 |
| EP3548514A1 (en) * | 2016-11-29 | 2019-10-09 | Regeneron Pharmaceuticals, Inc. | Methods of treating prlr positive breast cancer |
| TW201836647A (zh) * | 2017-04-06 | 2018-10-16 | 美商艾伯維有限公司 | 抗－ｐｒｌｒ抗體藥物軛合物（ａｄｃ）及其用途 |
| KR20200007905A (ko) | 2017-05-18 | 2020-01-22 | 리제너론 파마슈티칼스 인코포레이티드 | 사이클로덱스트린 단백질 약물 접합체 |
| ES3065816T3 (en) | 2017-06-07 | 2026-05-08 | Regeneron Pharma | Compositions and methods for internalizing enzymes |
| BR112020000127A2 (pt) | 2017-07-06 | 2020-07-07 | Regeneron Pharmaceuticals, Inc. | método para selecionar um hidrolisado de soja, e, glicoproteína |
| IL313068A (en) | 2017-11-07 | 2024-07-01 | Regeneron Pharma | Hydrophilic linkers for antibody drug conjugates |
| BR112020010615A2 (pt) | 2017-12-22 | 2020-10-27 | Regeneron Pharmaceuticals, Inc. | produto farmacêutico proteico, método e sistema para caracterizar impurezas de produto farmacêutico proteico e de fármaco de baixo peso molecular, método para produzir um anticorpo, anticorpo, e, usos do método e do sistema |
| IL275757B2 (en) | 2018-01-08 | 2025-08-01 | Regeneron Pharma | Steroids and antibody-conjugates thereof |
| MX2020008095A (es) | 2018-01-31 | 2020-09-24 | Regeneron Pharma | Sistemas y métodos para caracterizar variantes de tamaño y carga de impurezas de productos farmacológicos. |
| TWI786265B (zh) | 2018-02-02 | 2022-12-11 | 美商再生元醫藥公司 | 用於表徵蛋白質二聚合之系統及方法 |
| CN112040985A (zh) | 2018-02-07 | 2020-12-04 | 瑞泽恩制药公司 | 用于递送治疗性蛋白质的方法和组合物 |
| KR20200127979A (ko) | 2018-02-28 | 2020-11-11 | 리제너론 파마슈티칼스 인코포레이티드 | 바이러스 오염물질을 확인하기 위한 시스템 및 방법 |
| US12253490B2 (en) | 2018-03-19 | 2025-03-18 | Regeneron Pharmaceuticals, Inc. | Microchip capillary electrophoresis assays and reagents |
| US12259355B2 (en) | 2018-03-19 | 2025-03-25 | Regeneron Pharmaceuticals, Inc. | Microchip capillary electrophoresis assays and reagents |
| CA3246952A1 (en) | 2018-03-19 | 2025-10-31 | Regeneron Pharmaceuticals, Inc. | Microchip capillary electrophoresis assays and reagents |
| CN112074538B (zh) | 2018-04-30 | 2024-10-18 | 瑞泽恩制药公司 | 结合her2和/或aplp2的抗体和双特异性抗原结合分子、其缀合物和用途 |
| MX2020011546A (es) | 2018-05-09 | 2021-01-29 | Regeneron Pharma | Anticuerpos anti-msr1 y metodos de uso de los mismos. |
| TW202016125A (zh) | 2018-05-10 | 2020-05-01 | 美商再生元醫藥公司 | 用於定量及調節蛋白質黏度之系統與方法 |
| BR112020023145A2 (pt) | 2018-05-17 | 2021-02-02 | Regeneron Pharmaceuticals, Inc. | anticorpo anti-cd63 ou fragmento de ligação ao antígeno do mesmo, molécula de ligação ao antígeno biespecífica, proteína terapêutica de múltiplos domínios, polinucleotídeo composição farmacêutica, e, composto |
| CN120795059A (zh) | 2018-08-27 | 2025-10-17 | 瑞泽恩制药公司 | 拉曼光谱在下游纯化中的应用 |
| US11754569B2 (en) | 2018-08-30 | 2023-09-12 | Regeneron Pharmaceuticals, Inc. | Methods for characterizing protein complexes |
| US20220023434A1 (en) | 2018-12-19 | 2022-01-27 | The Board Of Trustees Of The Leland Stanford Junior University | Bifunctional Molecules for Lysosomal Targeting and Related Compositions and Methods |
| CN118027137A (zh) | 2018-12-21 | 2024-05-14 | 里珍纳龙药品有限公司 | 微管溶素及蛋白质-微管溶素偶联物 |
| WO2020146541A2 (en) | 2019-01-08 | 2020-07-16 | Regeneron Pharmaceuticals, Inc. | Traceless linkers and protein-conjugates thereof |
| EP3911682A4 (en) * | 2019-01-14 | 2023-03-15 | The Regents of the University of California | COMPOSITIONS AND METHODS TO MODULATE CELLULAR INTERNALIZATION |
| PL3857237T3 (pl) | 2019-01-16 | 2023-07-10 | Regeneron Pharmaceuticals, Inc. | Sposoby charakteryzowania mostka disiarczkowego |
| AU2020275406A1 (en) | 2019-05-13 | 2021-11-18 | Regeneron Pharmaceuticals, Inc. | Improved competitive ligand binding assays |
| CA3143373A1 (en) * | 2019-06-25 | 2020-12-30 | Tarveda Therapeutics, Inc. | Sstr-targeted conjugates and formulations thereof |
| US11814428B2 (en) | 2019-09-19 | 2023-11-14 | Regeneron Pharmaceuticals, Inc. | Anti-PTCRA antibody-drug conjugates and uses thereof |
| IL291020B2 (en) | 2019-09-24 | 2025-04-01 | Regeneron Pharma | Systems and methods for use in chromatography and regeneration |
| US12297451B1 (en) | 2019-10-25 | 2025-05-13 | Regeneron Pharmaceuticals, Inc. | Cell culture medium |
| MY207613A (en) | 2019-11-25 | 2025-03-06 | Regeneron Pharma | Sustained release formulations using non-aqueous emulsions |
| US12612444B2 (en) | 2019-11-26 | 2026-04-28 | University of Pittsburgh—of the Commonwealth System of Higher Education | T cell receptors targeting mutations in RNA splicing factors |
| US11835527B2 (en) | 2020-01-21 | 2023-12-05 | Regeneron Pharmaceuticals, Inc. | Deglycosylation methods for electrophoresis of glycosylated proteins |
| WO2021158962A2 (en) | 2020-02-06 | 2021-08-12 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | T cell receptors targeting defective dna repair proteins |
| US10822379B1 (en) | 2020-03-12 | 2020-11-03 | University of Pittsburgh—of the Commonwealth System of Higher Education | Molecules that bind to SARS-CoV-2 |
| EP4171653A2 (en) | 2020-06-24 | 2023-05-03 | Regeneron Pharmaceuticals, Inc. | Tubulysins and protein-tubulysin conjugates |
| GB202011993D0 (en) | 2020-07-31 | 2020-09-16 | Adc Therapeutics Sa | ANTI-IL 13Ra2 antibodies |
| IL300828A (en) | 2020-08-31 | 2023-04-01 | Regeneron Pharma | Asparagine feeding strategies to improve cell culture performance and reduce asparagine sequence variants |
| MX2023006077A (es) | 2020-11-25 | 2023-06-06 | Regeneron Pharma | Formulaciones de liberacion sostenida mediante emulsificacion por membrana no acuosa. |
| US12350374B2 (en) | 2020-12-17 | 2025-07-08 | Regeneron Pharmaceuticals, Inc. | Fabrication of protein-encapsulating microgels |
| US20240075158A1 (en) * | 2020-12-22 | 2024-03-07 | Jiangsu Hengrui Pharmaceutical Co., Ltd. | Complex of anti-il-4r antibody or antigen-binding fragment thereof and medical use thereof |
| AR124681A1 (es) | 2021-01-20 | 2023-04-26 | Abbvie Inc | Conjugados anticuerpo-fármaco anti-egfr |
| TW202233827A (zh) | 2021-01-20 | 2022-09-01 | 美商再生元醫藥公司 | 改良細胞培養中蛋白質效價的方法 |
| AR125585A1 (es) | 2021-03-03 | 2023-08-02 | Regeneron Pharma | Sistemas y métodos para cuantificar y modificar la viscosidad de proteínas |
| CA3211302A1 (en) | 2021-03-26 | 2022-09-29 | Ross Kenyon | Methods and systems for developing mixing protocols |
| BR112023024984A2 (pt) | 2021-06-01 | 2024-02-20 | Regeneron Pharma | Tampão de amostra de eletroforese aquosa, método para identificar contaminantes ou impurezas em uma amostra de droga proteica, e, kit |
| JP2024524614A (ja) | 2021-07-14 | 2024-07-05 | ライシア セラピューティクス， インコーポレイテッド | Ａｓｇｐｒ細胞表面受容体結合化合物及びコンジュゲート |
| TW202326138A (zh) | 2021-09-08 | 2023-07-01 | 美商再生元醫藥公司 | 用於定量抗體及其他含Ｆｃ蛋白之高通量及基於質譜之方法 |
| CA3232463A1 (en) | 2021-09-20 | 2023-03-23 | Philip Mellors | Methods of controlling antibody heterogeneity |
| JP2024538673A (ja) | 2021-10-07 | 2024-10-23 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ｐＨモデリング及び制御のシステム及び方法 |
| KR20240090312A (ko) | 2021-10-07 | 2024-06-21 | 리제너론 파아마슈티컬스, 인크. | Ph 미터 보정 및 교정 |
| MX2024005090A (es) | 2021-10-26 | 2024-07-19 | Regeneron Pharma | Sistemas y metodos para generar agua de laboratorio y distribuir agua de laboratorio a diferentes temperaturas. |
| US20230414775A1 (en) | 2021-12-29 | 2023-12-28 | Regeneron Pharmaceuticals, Inc. | Tubulysins and protein-tubulysin conjugates |
| JP2025508665A (ja) * | 2022-01-29 | 2025-04-10 | 上海盛迪医薬有限公司 | グルココルチコイドの薬物複合体 |
| CN114853890B (zh) * | 2022-03-16 | 2023-04-28 | 沈阳三生制药有限责任公司 | 一种prlr抗原结合蛋白及其制备方法和应用 |
| EP4493921A1 (en) | 2022-03-18 | 2025-01-22 | Regeneron Pharmaceuticals, Inc. | Methods and systems for analyzing polypeptide variants |
| CN120418653A (zh) | 2022-12-16 | 2025-08-01 | 里珍纳龙药品有限公司 | 评估色谱柱完整性的方法和系统 |
| WO2024158961A1 (en) | 2023-01-25 | 2024-08-02 | Regeneron Pharmaceuticals, Inc. | Mass spectrometry-based characterization of antibodies co-expressed in vivo |
| US20240245779A1 (en) | 2023-01-25 | 2024-07-25 | Regeneron Pharmaceuticals, Inc. | Methods of modeling liquid protein composition stability |
| WO2024163708A1 (en) | 2023-02-01 | 2024-08-08 | Regeneron Pharmaceuticals, Inc. | Asymmetrical flow field-flow fractionation with mass spectrometry for biomacromolecule analysis |
| EP4661914A1 (en) | 2023-02-09 | 2025-12-17 | Regeneron Pharmaceuticals, Inc. | Antibody-drug conjugates via inverse electron demand diels-alder reactions |
| US20240280551A1 (en) | 2023-02-22 | 2024-08-22 | Regeneron Pharmaceuticals, Inc. | System suitability parameters and column aging |
| TW202508625A (zh) | 2023-05-01 | 2025-03-01 | 美商再生元醫藥公司 | 使用苯酚或苯甲醇之多劑量抗體藥物產品 |
| WO2025054406A1 (en) | 2023-09-08 | 2025-03-13 | Regeneron Pharmaceuticals, Inc. | Methods and systems for assessing chromatographic column integrity |
| WO2025064403A2 (en) | 2023-09-18 | 2025-03-27 | Regeneron Pharmaceuticals, Inc. | Methods and systems for developing chromatography protocols |
| CN121925272A (zh) | 2023-09-29 | 2026-04-24 | 瑞泽恩制药公司 | 利用受控成核进行冻干 |
| WO2025085594A1 (en) | 2023-10-18 | 2025-04-24 | Regeneron Pharmaceuticals, Inc. | Rapid purification of monoclonal antibody from in-process upstream cell culture material |
| AU2024373307A1 (en) | 2023-11-02 | 2026-05-14 | Regeneron Pharmaceuticals, Inc. | Methods for reducing lipase activity using stress |
| TW202532435A (zh) * | 2023-11-30 | 2025-08-16 | 新加坡科技研究局 | 治療新生血管性眼疾之方法 |
| WO2025166281A1 (en) | 2024-02-01 | 2025-08-07 | Regeneron Pharmaceuticals, Inc. | Platform for charge-detection mass spectrometry analysis of aavs |
| WO2025175164A1 (en) | 2024-02-16 | 2025-08-21 | Regeneron Pharmaceuticals, Inc. | Methods of producing concentrated formulated drug substances comprising proteins, and concentrated formulated drug substance made by the methods |
| WO2025194043A1 (en) | 2024-03-15 | 2025-09-18 | Regeneron Pharmaceuticals, Inc. | Polysorbate and polyoxyethylene sorbitan as excipients for stable protein formulations |
| WO2025250777A1 (en) * | 2024-05-30 | 2025-12-04 | Jecho Laboratories, Inc. | Prolactin receptor (prlr)-specific antibody and uses thereof |
| WO2025259840A1 (en) | 2024-06-13 | 2025-12-18 | Regeneron Pharmaceuticals, Inc. | Methods and systems for scaled chromatography |
| WO2026025028A1 (en) | 2024-07-26 | 2026-01-29 | Regeneron Pharmaceuticals, Inc. | Methods of making ultra-high concentrated protein formulations using lyophilization |
| WO2026060350A1 (en) | 2024-09-13 | 2026-03-19 | Regeneron Pharmaceuticals, Inc. | Methods of improving photo stability and controlling formation of hmw species in biologic formulations, and biologic formulations produced by the methods |
| WO2026076201A2 (en) | 2024-10-03 | 2026-04-09 | Regeneron Pharmaceuticals, Inc. | Systems and methods for producing therapeutic proteins using single pass tangential flow filtration for in-line concentration and volume reduction of production pools |
| WO2026080597A1 (en) | 2024-10-08 | 2026-04-16 | Regeneron Pharmaceuticals, Inc. | Sustained delivery of biologics and non-aqueous manufacture of same |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US6429186B1 (en) | 1991-05-10 | 2002-08-06 | Genentech, Inc. | Ligand antagonists for treatment of breast cancer |
| AU3895299A (en) | 1998-05-12 | 1999-11-29 | Wen Y Chen | Use of anti-prolactin agents to treat proliferative conditions |
| US6867187B2 (en) | 2000-12-22 | 2005-03-15 | Trustees Of The University Of Pennsylvania | Composition and method for modulating somatolactogenic function |
| US6441163B1 (en) | 2001-05-31 | 2002-08-27 | Immunogen, Inc. | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
| US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
| WO2005058232A2 (en) | 2003-12-11 | 2005-06-30 | Tercica, Inc. | Methods and compositions for the treatment of prolactin-receptor related disorders |
| US8754031B2 (en) | 2004-03-08 | 2014-06-17 | Oncolix, Inc. | Use of prolactin receptor antagonists in combination with an agent that inactivates the HER2/neu signaling pathway |
| US7422899B2 (en) * | 2005-10-05 | 2008-09-09 | Biogen Idec Ma Inc. | Antibodies to the human prolactin receptor |
| WO2007051112A2 (en) | 2005-10-24 | 2007-05-03 | Invitrogen Corporation | Serum prolactin binding protein in epithelial carcinoma |
| EP3018144A1 (en) * | 2006-08-18 | 2016-05-11 | XOMA Technology Ltd. | Prlr-specific antibody and uses thereof |
| WO2009010398A1 (en) | 2007-07-18 | 2009-01-22 | Novo Nordisk A/S | Stabilized prolactin receptor antagonists |
| RU2487877C2 (ru) * | 2008-04-30 | 2013-07-20 | Иммьюноджен, Инк. | Высокоэффективные конъюгаты и гидрофильные сшивающие агенты (линкеры) |
| EP2332995A1 (en) | 2009-12-10 | 2011-06-15 | Bayer Schering Pharma Aktiengesellschaft | Neutralizing prolactin receptor antibodies and their therapeutic use |
| WO2012136519A1 (en) * | 2011-04-06 | 2012-10-11 | Bayer Pharma Aktiengesellschaft | Use of neutralizing prolactin receptor antibodies for the treatment and prevention of antiestrogen-resistant breast cancer |
| EP2530089A1 (en) * | 2011-06-03 | 2012-12-05 | Bayer Pharma Aktiengesellschaft | Neutralising prolactin receptor antibody Mat3 and its therapeutical use |
| CN102746402A (zh) | 2012-07-09 | 2012-10-24 | 南京医科大学 | 全人源抗人催乳素受体单链抗体及其应用 |
| US8883979B2 (en) | 2012-08-31 | 2014-11-11 | Bayer Healthcare Llc | Anti-prolactin receptor antibody formulations |
| EP2935331B1 (en) * | 2012-12-24 | 2018-02-28 | AbbVie Inc. | Prolactin receptor binding proteins and uses thereof |
| JP2016515515A (ja) | 2013-03-15 | 2016-05-30 | バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ | 抗プロラクチン受容体抗体製剤 |
| EP3964237B1 (en) | 2013-03-15 | 2026-02-18 | Regeneron Pharmaceuticals, Inc. | Biologically active molecules, conjugates thereof, and therapeutic uses |
| US9545451B2 (en) | 2013-08-21 | 2017-01-17 | Regeneron Pharmaceuticals, Inc. | Anti-PRLR antibodies and methods for killing PRLR-expressing cells |
| TWI641620B (zh) | 2013-08-21 | 2018-11-21 | 再生元醫藥公司 | 抗－ｐｒｌｒ抗體及其用途 |
| TW201836647A (zh) | 2017-04-06 | 2018-10-16 | 美商艾伯維有限公司 | 抗－ｐｒｌｒ抗體藥物軛合物（ａｄｃ）及其用途 |
-
2014
- 2014-08-19 TW TW103128378A patent/TWI641620B/zh not_active IP Right Cessation
- 2014-08-20 MX MX2016002150A patent/MX370787B/es active IP Right Grant
- 2014-08-20 MY MYPI2016000311A patent/MY179851A/en unknown
- 2014-08-20 KR KR1020167006556A patent/KR102343315B1/ko not_active Expired - Fee Related
- 2014-08-20 CN CN201480055822.8A patent/CN105793286B/zh not_active Expired - Fee Related
- 2014-08-20 EA EA201600190A patent/EA201600190A1/ru unknown
- 2014-08-20 SG SG11201601211TA patent/SG11201601211TA/en unknown
- 2014-08-20 NZ NZ716612A patent/NZ716612A/en not_active IP Right Cessation
- 2014-08-20 WO PCT/US2014/051831 patent/WO2015026907A1/en not_active Ceased
- 2014-08-20 AU AU2014308920A patent/AU2014308920B2/en not_active Ceased
- 2014-08-20 JP JP2016536405A patent/JP6621412B2/ja active Active
- 2014-08-20 CA CA2920369A patent/CA2920369C/en active Active
- 2014-08-20 EP EP14761739.3A patent/EP3036257B1/en active Active
- 2014-08-20 US US14/464,297 patent/US9302015B2/en active Active
- 2014-08-21 UY UY35712A patent/UY35712A/es not_active Application Discontinuation
-
2016
- 2016-02-04 IL IL243974A patent/IL243974B/en active IP Right Grant
- 2016-02-19 CL CL2016000376A patent/CL2016000376A1/es unknown
- 2016-02-22 PH PH12016500349A patent/PH12016500349B1/en unknown
- 2016-02-23 US US15/051,580 patent/US9688764B2/en active Active
-
2017
- 2017-05-22 US US15/601,884 patent/US10106616B2/en active Active
-
2018
- 2018-09-18 US US16/134,838 patent/US10683354B2/en active Active
-
2019
- 2019-09-26 JP JP2019175762A patent/JP2020023511A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7754906B2 (ja) | Ｂｃｍａモノクローナル抗体薬剤コンジュゲート | |
| RU2019138337A (ru) | Конъюгаты на основе антитела, содержащие агонист toll-подобного рецептора, и виды комбинированной терапии | |
| JP6621412B2 (ja) | 抗ｐｒｌｒ抗体及びその使用 | |
| JP2018534933A5 (enExample) | ||
| JP2017510559A5 (enExample) | ||
| CN110088138A (zh) | 抗steap2抗体、抗体药物偶联物和结合steap2和cd3的双特异性抗原结合分子以及其用途 | |
| KR20170068458A (ko) | 항-ｎｋｇ2ａ 항체를 사용한 치료 요법 | |
| JP2007536932A5 (enExample) | ||
| KR20160037130A (ko) | 신규한 항체 접합체 및 이의 용도 | |
| CN111655725A (zh) | 用于治疗癌症的组合产品 | |
| WO2023025303A1 (zh) | 抗cldn-18.2抗体药物偶联物及其用途 | |
| EA046403B1 (ru) | Конъюгат моноклонального антитела к bcma и лекарственного средства | |
| EA052269B1 (ru) | Конъюгат моноклонального антитела к bcma и лекарственного средства |